

State of Connecticut
Medical Marijuana Producer License

RESPONSE to RFA
Volume 5 of 5
November 2013

TABLE OF CONTENTS
THERAPLANT, LLC RFA SUBMITTAL

Volume I

	<u>Page#</u>
Appendix A	0001-0120
Appendix B	0121-0122
Appendix C	0123-0237
Section A-2	0238-0310

Volume II

Section A-3	0311-0573
-------------------	-----------

Volume III

Section B-1	0574-0575
Section B-2	0576
Section B-3	0577
Section B-4	0578-0580
Section B-5	0581-0583
Section B-6	0584-0587
Section B-7	0588
Section B-8	0589-0713
Section C-1	0714-0717
Section C-2	0718-0909
Section D-1	0910-0916

Volume IV

Section E-1	0917-0996
Section E-2	0997-1068
Section E-3	1069-1131
Section E-4	1132-1133
Section E-5	1134-1152
Section E-6	1153-1154
Section E-7	1155-1317

TABLE OF CONTENTS
THERAPLANT, LLC RFA SUBMITTAL (CONT.)

<u>Volume V</u>	<u>Page#</u>
Section F-1	1318-1335
Section G-1.....	1336-1370
Section G-2.....	1371-1372
Section H-1.....	1373-1384
Section I-1	1385-1388
Section I-2	1389-1393
Section I-3	1394-1401
Section I-4	1402-1412
Section I-5	1413-1418
Section I-6	1419-1444

Supplemental Volume

Section SV-1.....	1445-1616
Section SV-2.....	1617-1833

Notes to Application

Freedom of Information Act

Theraplant has provided material for this application that includes the following:

1. Theraplant business information, created or obtained by Theraplant at significant expense that is not publicly available in the industry in which Theraplant operates. This information has independent economic value to Theraplant. If this information is obtained by Theraplant's competitors, it would unfairly advantage such competitors to Theraplant's significant economic detriment.

For these reasons, this information constitutes "trade secrets" and/or "commercial or financial information given in confidence" pursuant to Conn. Gen. Stat. § 1-210(b)(5)(A) and (B), and is therefore exempt from disclosure under the State of Connecticut Freedom of Information Act, Conn. Gen. Stat. § 1-200 et seq.

2. Information constituting "statements of personal worth or personal financial data required by a licensing agency and filed by an applicant with such licensing agency to establish the applicant's personal qualification for the license. . . applied for. . ." and/or "records" or "tax returns" pursuant to Conn. Gen. Stat. § 1-210(b)(8) and/or (10), respectively.

Therefore, this information is exempt from disclosure under the State of Connecticut Freedom of Information Act, Conn. Gen. Stat. § 1-200 et seq.

Each page containing information meeting the description(s) of (1) or (2) above (or both) shall be identified by the presence of a stamp on the bottom of such page stating the following:

FOIA EXEMPT UNDER CGS § 1-210(b)(5)(A) & (B)

AND/OR CGS § 1-210(b)(8) AND/OR (10)



Connecticut Department of Consumer Protection
Medical Marijuana Producer License
Request for Application

Section F-1

Agricultural and Production Experience

F.1 AGRICULTURAL AND PRODUCTION EXPERIENCE

The team leading agriculture and bringing production experience to Theraplant is comprised of six key professionals. They have been brought together to build on existing growing experience, adhere to stringent compliance standards and create an operational and procedural environment mirroring what one would find in the pharmaceutical industry. It is the combination of extensive experience growing cannabis for medicinal purposes coupled with oversight from pharmaceutical industry experts that sets the Theraplant team apart.

Below, please find brief profiles of our team members along with a description of the role each of them will play at Theraplant.

Jonathan Lane.

Mr. Lane has documented over 100 varieties of flowering cannabis in the production areas he set up in Colorado, and cultivated continuous, consistently superior harvests. Jonathan also brings a deep understanding of plant pests, having studied many varieties and their behaviors; Including root aphids, russet mites and spider mites. This experience has yielded a true expertise in effective pest treatments and enabled Jonathan to develop a systematic method to train his teams in best pest management practices. He will work directly with the team setting up the grow rooms at Theraplant to prevent pest attacks on crops.

Please see exhibit F.1-1_lane_bio

Mike Guiernieri, PhD

Dr. Guiernieri is a molecular and biomedical chemist trained in structure based drug design and will work on new strain development. Dr. Guiernieri's post doctorate work in the bio-fuel arena has also made him our resident expert on extraction of cannabis oil using the Supercritical CO2 technique which is preferable to the standard LIPID extraction method including multiple solvents. The SupercriticalCO2 fluid extraction methodology and precision technique is the same used to extract caffeine from coffee, and allows Theraplant to create a more pure cannabis oil concentrate for patients requiring a smokeless delivery method for their prescribed medication.

Please see exhibit F.1-2_Guiernieri_bio

Tim Coleman, Ph.D.

Dr. Coleman is currently the CEO of Blue Ocean Bio-manufacturing. Dr. Coleman was recently the leader of the Biomedical Strategy Group in Price Waterhouse Coopers. Prior to joining PwC, Dr. Coleman was president, CEO and co-founder of BioCache

F.1 AGRICULTURAL AND PRODUCTION EXPERIENCE

Pharmaceuticals, Inc., a Richmond, Virginia-based biopharmaceutical company primarily engaged in the research and development of cancer vaccines. There, he was a National Cancer Institute funded principal investigator studying the interaction of cancer vaccines with Toll-Like Receptors (TLRs) to induce a clinically relevant immune response. Additionally, he successfully led the firm's growth through early stage funding, strategic expansion and eventual establishment of a non-founding executive leadership team. Dr. Coleman also has over 20 years' experience in research and development, including expertise in genomics, proteomics, molecular biology and recombinant protein expression. Dr. Coleman will lead the design of Theraplant's research studies.

Please see exhibit F.1-3_Coleman_bio

Moria Feigherty-Ross & Peter Rafa

Ms. Feigherty and Mr. Rafa are principles of 20/20QC, a medical quality control and compliance firm. They have dedicated their energies to creating, implementing and verifying Theraplant's growing and production protocols using their combined 30 years of experience in the pharmaceutical industry. They bring documentation and testing expertise, a thorough knowledge of environmental control and post control procedural methodology and a deep understanding of and respect for regulatory affairs -- having worked with and having received approval from the FDA. Together, Ms. Feigherty-Ross and Mr. Rafa will continuously oversee our agriculture and production systems and our documentation and review processes for quality assurance, quality control, compliance, and validation at every turn. Their work will be particularly essential during our first year of operation.

Please see exhibit F.1-4_Feigherty_Rafa_bios

Annik Chamberlin

Ms. Chamberlin is a pharmacist, with expertise in custom compounded medications varying dosages and delivery methods to suit doctor's instructions and their respective patients. Ms. Chamberlin owns Beacon Prescriptions Compounding pharmacy in Southington, CT. Ms. Chamberlin will act as a liaison with the pharmacists at the approved dispensaries interfacing on a pharmacist to pharmacist level to gather information on market and product need which will inform Theraplant production and product development. Ms. Chamberlin has specific experience in "making" medicine for her patients when a suitable dosage of delivery mechanism is not commercially available. Ms. Chamberlin will oversee the production of capsules initially. Her insights from working in the field with doctors, nurses, caretakers and serving the local

F.1 AGRICULTURAL AND PRODUCTION EXPERIENCE

community will allow her unique insight into new medications and delivery methods that Theraplant can create or develop in the future.

Please see exhibit F.1-4_Chamberlin_bio

Jonathan "Jon" Lane
Horticulturalist
Theraplant * Jon@theraplant.co

Accomplished, motivated professional with 4 years of progressive experience in large scale indoor medical cannabis cultivation.

- * Strong skills in large scale cannabis cultivation management ensuring consistent production of quality product.
- * Innovative, entrepreneurial approach to conceiving, researching, designing, developing, and improving policies and processes. Successful in proposing and implementing key initiatives, mitigating risk and driving achievement of desired results in complex indoor cultivation environments.
- * Strong background of working with diverse varieties of cannabis. In depth knowledge of known classifications, origins, and plant specific traits and qualities.
- * Profound knowledge and understanding of a wide spectrum of indoor cannabis cultivation properties including soils, inert mediums, hydroponic systems, nutrients and their relation to plant processes, lighting, environmental controls, Integrated Pest Management programs, varieties of indoor pests/ pathogens and molds, stages of photosynthesis and plant life cycles, differences in cannabis species, pollinations and selective breeding, and identification of disease resistant species through observation. Systematic execution of production through propagation of seeds and clones, and successive growth of vegetative and flowering cannabis plants utilizing proven methods of specific, learned cultivation techniques.
- * Extensive history of work force management. Outgoing, credible communicator with outstanding ability to connect meaningfully with individuals promoting a strong and passionate work environment.

Experience

GRASS ROOTS HEALTH AND WELLNESS Denver, CO

2011- 2013

Personally manage all horticultural production of medicinal cannabis.

- * Responsible for operating all phases of production from seed and clone propagation, vegetative plants, and flowering plants through end of growth cycle.
- * Managed and trained employees in all aspects of company protocol and policies regarding cultivation including mixing and calibration of nutrients, environmental monitoring, water treatments and filtration, and irrigation systems.
- * Developed and organized grow systems in all phases of growth. Implemented strategies for improved consistency and efficiency of production.
- * Responsible for oversight of nutrient regimens, grow mediums, grow systems and plant maintenance including plant support systems, pruning techniques for maximum yield and plant health, foliar spray applications, and development and implementation of Integrated Pest Management programs.
- * Developed safety protocols and training for handling of hazardous or potentially hazardous materials used for plant and water treatments, awareness of unsafe nutrients and pesticides, use of personal protective gear when needed, and safe use and maintenance of horticultural tools and equipment.
- * Documented over 100 varieties of flowering cannabis in the production areas, as well as success and failures of various techniques utilized in propagation and vegetative growth of plants. Documented plant pests of many varieties and their behaviors including root aphids, russet mites, and spider mites to understand effective treatments and pest management.
- * Participated in company meetings to analyze strain selections, patient responses to particular varieties, and increase overall quality and efficiency of company products and sales based on statistical data.

LOTUS FARMS Denver, CO

2010-2011

Assistant Manager of horticulture and production of medicinal cannabis.

- * Assisted in construction of grow rooms.
- * Produced cannabis in coco coir and soil mediums, deep water culture hydroponic systems.
- * Assisted lead grower in nutrient mixing, irrigation, operation of hydroponic systems, operation of environmental systems and monitoring, and product processing and packaging.

JGL CONSTRUCTION, INC Denver, CO/ Durango, CO

2001-2010

Owned and operated residential construction company for ten years.

- * Contractor of various aspects of home building including framing, siding, windows, doors, decks, sunrooms, and log structures.
- * Organized and directed labor crews on daily basis to perform and complete projects in multiple locations.
- * Maintained stringent work schedules to complete projects in timely manner.
- * Responsible for interpreting blueprints for labor and material cost estimates.
- * Built long lasting relationships and partnerships statewide through continued execution of quality workmanship.
- * Managed high cost budgets of custom home, multi family condominium, and commercial projects through completion.
- * Responsible for safety and on the job training for employees.
- * Operated and maintained heavy equipment, tools, and scaffolding.
- * Worked hands on for duration of business.

CURRICULUM VITAE
Michael Thomas Guarnieri, Ph. D.

EDUCATION

2004-2009 **Ph.D., Biochemistry and Molecular Genetics**
University of Colorado, School of Medicine, Denver, CO
Joint degree in the Program in Structural Biology and Biophysics
Research Advisor: Rui Zhao, PhD

- Thesis: "Structural and Biochemical Studies of the PhoPQ Two-Component System."

2000-2003 **B.A., Chemistry with Honors**
Rhode Island College, Providence, Rhode Island

RESEARCH EXPERIENCE

2012-Present **Senior Research Scientist, Systems Biology**
National Renewable Energy Laboratory, Golden, CO
National Bioenergy Center, Applied Biology

- Coupled functional genomics and microbial engineering in order to optimize biochemical and biofuel production in algal, bacterial, and fungal systems.
- Developed enhanced lignin degradation and conversion capacity in fungal and bacterial systems.
- Developed succinate hyper expression strain of *Pseudomonas putida*.
- Contributed to the development of enhanced pentose sugar-utilizing strain of *Zymomonas mobilis*.
- Identified and mapped algal cell-signaling pathways critical to lipid biosynthesis.

2009-2012 **Air Force Office of Scientific Research, Postdoctoral Fellow**
National Renewable Energy Laboratory, Golden, CO
National Bioenergy Center

Research Advisors: Philip T. Pienkos, PhD and Al Darzins, PhD

- Developed *de novo* transcriptome-to-proteome pipeline in oleaginous alga, *Chlorella vulgaris*.
- Led team to complete genome sequencing of *C. vulgaris*.

- Gene expression analysis of *C. vulgaris* during lipid accumulation.
- Developed high-throughput sugar transport assay in *Z. mobilis*.
- Generated library of pentose sugar transporters in *Z. mobilis*.

2004-2009	Doctoral Candidate, Biochemistry and Molecular Genetics
	<i>University of Colorado, School of Medicine, Denver, CO</i>
	Department of Biochemistry and Molecular Genetic
	<ul style="list-style-type: none"> • Examined potential small molecule and peptide inhibitors targeting bacterial histidine kinases and response regulators. • Determined crystal structure of bacterial histidine kinase PhoQ in complex with radicicol. • Developed high-throughput fluorometric assay to screen small molecule libraries. • Refined the co-crystal structure of bacterial phosphatase CheX in complex with response regulator CheY.
1999-2004	Research Assistant
	<i>Brown University, Providence, Rhode Island</i>
	Department of Pathobiology and Medicine,
	<u>Research Advisors:</u> Jack Wands, MD and Shuping Tong, MD/PhD
	<ul style="list-style-type: none"> • Investigated viral secretion and virus-host interaction using Hepatitis B Virus as a model system.

TEACHING EXPERIENCE

2012-Present	Adjunct Professor
	<i>Center for Health Sciences, Community College of Aurora, Denver, CO</i>
	Department of Chemistry
	<u>Courses taught:</u> CHE 101 – Introduction to Chemistry
2008-2009	Instructor
	<i>University of Colorado Health Sciences Center, Denver, CO</i>
	<u>Courses Taught:</u> Protein Structure and Function
	Introduction to Biophysical Methods
2007	GEMS Mentor , Metro State College of Denver, Denver, CO.

HONORS AND AWARDS

- 2012 Woodrow Wilson Center Scholar, MIT Program in Emerging Technologies
- 2009 Air Force Office of Scientific Research Postdoctoral Fellowship
- 2009 Colorado Center for Biofuels and Biorefineries Postdoctoral Fellowship
- 2008 AAAS Excellence in Science Award
- 2008 University of Colorado Structural Biology Seminar Committee; Student Representative
- 2007 University of Colorado, Research Symposium Award Recipient
- 2003 Sigma Xi Honor Society, Rhode Island College Chapter

TECHNICAL SKILLS

Molecular biology subcloning and site-directed mutagenesis, Gibson assembly, protein expression and purification using both IEX and SEC, gas chromatography, HPLC, xray crystallography, NMR, fluorometry, peptide synthesis, proteomic analysis, RNAseq and transcriptomic analysis, small molecule high-throughput screening, high-throughput assay development, small molecule-protein binding assays, RNA extraction, quantitative RT-PCR, morpholino gene-silencing.

PAST, ACTIVE, AND PENDING GRANT SUPPORT

- 2013-2015 **ARPA-E DOPT100020013** - Bio-GTL: Novel Biocatalyst for conversion of natural gas into diesel fuel: \$1,276,000
- 2012-2015 **DOE LRD 06511301** - Two-component signal systems involved in algal nitrogen assimilation and the potential for increased lipid productivities: \$650,000
- 2012 **DOE LRD 06511103** - Genome sequencing for the investigation of lipid-regulating signaling systems in *Chlorella vulgaris*: \$49,000
- 2011-2012 **AFOSR IAG-08-1705**: Examination of post-transcriptional regulation of lipid accumulation in oleaginous microalgae: \$196,000
- 2009-2011 **AFOSR WFC310001**: Proteomic analysis of TAG accumulation in an unsequenced microalga: \$576,000
- 2009 **Colorado Center for Biofuels and Biotechnology**, Postdoctoral Fellowship (declined): \$180,000

PROFESSIONAL SERVICE

2012 Woodrow Wilson Center EPA Forum on Synthetic Biology
2012 Editor, Advances in Botanical Research
2012 *Ad hoc* reviewer for *Science*
2012 *Ad hoc* reviewer for *PLoS One*
2011 Reviewer, EPA Small Business Innovation Research (SBIR) Program
2011 Reviewer, Strategic Projects Grants Program, The Natural Sciences and Engineering Research Council of Canada (NSERC)
2010 *Ad hoc* reviewer for *Applied Energy*

AMATEUR AND PROFESSIONAL MEMBERSHIPS

- American Chemical Society
- American Association for the Advancement of Science
- American Crystallographic Association
- Algae Biomass Organization
- CERT: Colorado Evolution Response Team
- Environment Colorado

PUBLICATIONS

Guarnieri MT. Comparative proteomics lends insight into genotype-specific pathogenicity. *Proteomics*, 2013, *Manuscript in Press*.

Yang S, **Guarnieri MT**, Smolinski S, Ghirardi M, and Pienkos PT. De Novo Transcriptomic Analysis of Hydrogen Production in the Green Alga *Chlamydomonas moewusii* through RNA-Seq. *Biotechnol Bioeng*, 2013, *Manuscript in Press*.

Guarnieri MT, Nag A, Yang S, and Pienkos PT. Proteomics Analysis of *Chlorella vulgaris*: Target Identification for Strain Engineering. *J. Proteomics*, 2013, *Manuscript in Press*.

Guarnieri MT, et al. Complex Systems Engineering: A Case Study for an Unsequenced Microalga. *Engineering Complex Phenotypes in Industrial Strains*. John Wiley and Sons, Inc., 2012.

Guarnieri MT, Nag A, Smolinski SL, Darzins A, Seibert M, Pienkos PT. Examination of Triacylglycerol Biosynthetic Pathways via *De Novo* Transcriptomic and Proteomic Analyses in an Unsequenced Microalga. *PLoS ONE* 2011 Nov; 6(10): e25851.

Guarnieri MT, Blagg BSJ, Zhao R. A high-throughput TNP-ATP displacement assay for screening inhibitors of ATP-binding in bacterial histidine kinases. *Assay Drug Dev Technol*. 2011 Apr;9(2): 174-83.

Ito K, Qin Y, **Guarnieri MT**, Garcia T, Kwei K, Mizokami M, Zhang J, Li J, Wands JR, and Tong S. Hepatitis B Virus secretion is impaired by single amino acid changes in the small envelope protein and rescued by a novel glycosylation site. *J Virol*. 2010 Dec;84(24):12850-61.

Pazy Y, Motaleb MA, **Guarnieri MT**, Charon NW, Zhao R, Silversmith RE. Identical phosphatase mechanisms achieved through distinct modes of binding phosphoprotein substrate. *Proc Natl Acad Sci*. 2010 Feb 2;107(5):1924-9.

Guarnieri MT, Zhang L, Shen J, Zhao R. The Hsp90 Inhibitor radicicol interacts with the ATP-binding pocket of bacterial sensor kinase PhoQ. *J Mol Biol*. 2008 May 23;379(1): 82-93. PDB Deposits: 3cgy and 3cgz

Zhang L, Shen J, **Guarnieri MT**, Heroux A, Yang K, Zhao R. Crystal Structure of the C-terminal domain of splicing factor Prp8 carrying retinitis pigmentosa mutants. *Protein Science*. 2007 Jun 16(6): 1024-31.

PDB Deposits: 2p87 and 2p8r

Chen Y, **Guarnieri MT**, Vasil AI, Vasil ML, Mant CT, Hodges RS. Role of peptide hydrophobicity in the mechanism of action of alpha-helical antimicrobial peptides. *Antimicrob Agents Chemother*. 2007 Apr 51(4): 1398-406.

Guarnieri M, Kim, KH, Bang G, Li J, Zhou Y, Tang X, Wands J, Tong S. Point Mutations Upstream of Hepatitis B Virus Core Gene Affect DNA Replication at the Step of Core Protein Expression. *J Virol*. 2006 Jan 80(2):587-595

Bang G, Kim KH, **Guarnieri M**, Zoulim F, Kawai S, Li J, Wands J, Tong S. Effect of mutating the two cysteines required for HBe antigenicity on hepatitis B virus DNA replication and virion secretion. *Virology*. 2005 Feb 5;332(1):216-24.

Khan N, **Guarnieri M**, Ahn SH, Li J, Zhou Y, Bang G, Kim KH, Wands JR, Tong S. Modulation of hepatitis B virus secretion by naturally occurring mutations in the S gene. *J Virol*. 2004 Apr;78(7):3262-70.

PATENTS AND RECORDS OF INVENTION

Guarnieri MT, et al. Biological conversion process for production of biofuels, chemicals, and intermediates in the absence of fixed nitrogen. 2013 NREL IR# Pending.

Guarnieri MT and Knoshaug EP. Metabolic Pathway regulation systems used for concurrent algal production of biomass and lipids. 2011 NREL IR# 12-00007.

Tim Coleman

Greater Boston Area

CEO at Blue Ocean Biomanufacturing

Summary

Before co-founding Nemucore Medical Innovations, Tim was the leader of the Biomedical Strategy Group in PricewaterhouseCoopers Health Industries Practice. Residing in the firm's Boston office, Dr. Coleman worked with health science companies, delivering advisory services including business development strategies, intellectual property protection and management systems, R&D planning and operations, technology valuation, and commercialization strategies. He was also the lead author of the firm's co-sponsored report Super Cluster: Perspectives, Opinions and Facts from the Massachusetts Life Sciences Industry in 2007 & 2008.

Prior to joining PricewaterhouseCoopers, Dr. Coleman was president, CEO and co-founder of BioCache Pharmaceuticals, Inc., a Richmond, Virginia-based biopharmaceutical company primarily engaged in the research and development of cancer vaccines. There, he was a National Cancer Institute funded principal investigator studying the interaction of cancer vaccines with Toll-Like Receptors (TLRs) to induce a clinically relevant immune response. Additionally, he successfully led the firm's growth through early stage funding, strategic expansion and eventual establishment of a non-founding executive leadership team.

Dr. Coleman also has served as a technical adviser to venture capital firms, assessing the feasibility of life sciences technologies in biotechnology business plans. He is an elected member of the Massey Cancer Center, an internationally recognized center of excellence for cancer research and education.

A frequent guest lecturer and panelist, Dr. Coleman has spoken on numerous academic and industry association conferences, including at Massachusetts Legislative Life Science Caucus, BIO, MIT, Boston University, Virginia Biotechnology Association, Denver Entrepreneurship Council, and the Massachusetts Office for International Trade and Investment.

Biomedical start-up Executive
Technology License Negotiation
Business Development
New Venture Creation

Experience

CEO at Blue Ocean Biomanufacturing
May 2012 - Present (1 year 7 months)

CEO and co-Founder at BEAN

June 2010 - Present (3 years 6 months)

The Capital Market for Apps

Personalized Medicine Specialist at PricewaterhouseCoopers

August 2008 - Present (5 years 4 months)

CEO & President, co-Founder at Nemucore Medical Innovations, Inc.

July 2008 - Present (5 years 5 months)

Nemucore Medical Innovations Inc. is a nanomedicine company focused on providing nanoengineered solutions to "deliver the undeliverable" and improve the therapeutic index of drugs.

Specialist at Apple Retail

November 2009 - May 2010 (7 months)

Collaboration to expand my entrepreneurial effort outside biotechnology

Manager, Pharma and Life Sciences Practice at PricewaterhouseCoopers

January 2005 - July 2008 (3 years 7 months)

1 recommendation available upon request

Member at Massey Cancer Center

February 2001 - December 2004 (3 years 11 months)

The Massey Cancer Center's mission is to serve the Commonwealth of Virginia and the nation as an internationally recognized center of excellence in research, education, and patient care.

Members are dedicated to improving the quality of human life through the development of effective means for the prevention, control, and ultimately the cure of cancer. The core of this mission is the facilitation of interdisciplinary cancer research to harness the significant scientific and clinical resources of Virginia Commonwealth University and the Medical College of Virginia.

President at BioCache Pharmaceuticals, Inc.

November 1997 - March 2004 (6 years 5 months)

BioCache Pharmaceuticals, Inc. is focused on becoming a leader in the development of proprietary immunotherapeutic products for the treatment and prevention of cancer. Responsibilities focused on securing institutional venture financing, directing the expansion of R&D activities of the core immunology technology, and developing multiple external relationships. Leadership in this role led to the recruitment of several high profile university collaborators and preparing for the transition to a clinical development firm.

Education

Boston University - School of Management

MBA, Finance & Entrepreneurship, 2002 - 2004

Activities and Societies: Winner of the BU business plan competition;
Graduate Assistant for the Entrepreneurial Management Institute;

Virginia Commonwealth University School of Medicine

Ph.D., Molecular Biophysics & Biochemistry, 1993 - 1998

Worcester Polytechnic Institute

B.S., Biochemistry, August 1989 - May 1993

Honors And Awards

1. National & Regional Winner, PricewaterhouseCoopers's Chairman's Award July '07
2. National & Regional Winner, PricewaterhouseCoopers's Chairman's Award July '06
3. First Runner-Up GSAS Harvard Biotechnology Club Business Plan Competition June 9, 2004
4. Semi-Finalist of the MIT \$50K Business Plan Competition, May 7, 2004
5. Winner of the Boston University \$5K Business Plan Competition March 25, 2003

Interests

Boston Marathon

Moria Feighery-Ross

Summary

Ms. Feighery-Ross' 6+ years of consulting work for the pharmaceutical manufacturing industry spans startups to multinational corporations and Contract Manufacturing Operations. She has qualified manufacturing facilities, equipment, and utilities, as well as validating Computer Systems and Production Processes for clinical and commercial product lines of oral solid dosage forms, transdermal delivery systems, drug-device combinations and medical devices. This experience also includes qualifying manufacturing sites subject to Drug Enforcement Agency guidelines. She is experienced in risk assessment and risk-based validation, personnel training, and all phases of development of quality systems.

Experience

20/20 Quality Consulting, LLC

September 2013 - Present

Managing Member

20/20 was founded to provide quality systems, quality assurance, validation, and technical support to businesses entering and manufacturing within the regulated life sciences industry.

Pharmatech Associates Consultant

January 2007 – Present

Provided engineering, quality assurance, validation and technical support to regulated life sciences industry consultancy. Clients include Johnson & Johnson, Watson Pharmaceutical, Novo Nordisk, and others.

Project Highlights

- Validation Master Plan generation for new manufacturing facility/equipment for oral solid dosage manufacturer.
- Validation of new pharmaceutical facility including BMS, utility and facility qualification, and process move validation for commercial production medical device manufacturer.
- Validation of new pharmaceutical facility including multiple custom process equipment for drug-device combination manufacturer in scale-up from clinical to commercial production.
- Generation/Execution of solid dosage formulation equipment and facility validation, including extensive vendor interaction and troubleshooting.

Internal Responsibilities

- Creation of Training program exercises, presentations and SOPs

Jeff's Diesel Works

December 2005-December 2006

Mechanic

In-frame and in-shop overhauls of heavy diesel engines providing motive and generative power for tugboats, fishing boats and pleasure craft.

Various locations: San Diego, CA and Portland, OR July 1999-September 2004

Veterinary Technician

Induce and monitor anaesthesia, dental cleanings, intensive care services, laboratory analysis of blood, urine and other samples, clinical intake and release procedures, radiology and pharmacy services in a client-based atmosphere.

UC San Diego and Stanford University

1997-98, 2000-2001

Undergraduate Researcher

Silicon surface chemistry and photoelectrolithography; front-end semiconductor manufacturing, novel cell culture techniques.

Education

- B.S. Biology: University of California, San Diego. (2001)

Peter Rafa

Summary

Mr. Rafa has over twelve years of engineering, project management, validation, and quality management experience in the regulated life science industry. Mr. Rafa is experienced with quality system regulation, and has designed and implemented entire Quality Management Systems for industry clients. Mr. Rafa has extensive hands-on experience with process, equipment, facility, process supporting utilities, and computer control systems validation within the pharmaceutical, biotech, and medical device industries. He is a facilitator of collaboration among project stakeholders, as well as a critical and innovative thinker to help bring the best solutions forward in a timely manner.

Experience

20/20 Quality Consulting, Walnut Creek, CA September 2013 – Present
Managing Member

20/20 Quality Consulting LLC was founded to provide quality assurance, compliance, validation, planning, and technical services to business entering and operating within the regulated life sciences industry.

Pharmatech Associates, Hayward, CA **October 2001 – Present**
Associate Director

Provided engineering, quality assurance, validation, project management, and internal company management to regulated life sciences industry consultancy. Clients include Novartis Pharmaceuticals, Gilead Sciences, Johnson & Johnson (and multiple subsidiaries), Intelliject, Roche, Genentech, and others.

Project Highlights

- Management/Scheduling/Validation Master Plan generation for new manufacturing building for medical device manufacturer with 180,000 square foot clean room.
- Developed Environmental Monitoring Program from Policy down to the SOP level for pharmaceutical start-up.
- Management/Execution of new manufacturing building in preparation of PAI audit for combination pharmaceutical/medical device product.
- PM/Lead Engineer validation of new pharmaceutical facility including BOD and modification of HVAC design/air balance, automation and characterization studies for automated processes.
- Managed simultaneous process development and qualification of 1 billion annual oral solid dosage facility.
- Managed Change Control process for a filling/repackaging line.
- Management/Generation/Execution of solid dosage formulation equipment and facility validation
- Participated in pre-Pre Approval Inspection assessments of Medical Device, Biotech, and Pharma clients.
- Designed and managed Document Control systems for pharmaceutical start-up
- Validation Master Plan development for pharmaceutical bulk chemical manufacturer.
- Designed and Implemented reconciliation program for DEA-controlled packaging operation
- Able to direct many domestic and international projects of varying size (from single suite manufacturing build-outs up to multi-product campus capital projects simultaneously and ensures schedules, budgets, and technical project goals are met.

Internal Responsibilities

- Over 10 years of experience in sales, scoping, estimating, and proposal writing
- Management of over 10 direct reports

Education

- B.S. in Chemical Engineering: Johns Hopkins University, Baltimore, MD. (2001)
- Class of 1997, Fairfield High School, Fairfield, CT

Annik Chamberlin, PharmD

Profile: Annik Chamberlin is the Chief Pharmacist and Co-Owner of Beacon Prescriptions Compounding Pharmacy in Southington, CT. She has been a licensed pharmacist for nine years, and has run her own community pharmacy practice since 2010. Her pharmacy is known for outstanding service and Dr. Chamberlin is recognized for her interpersonal skills and track record of establishing positive relationships with patients/caregivers, pharmaceutical representatives/manufacturers, medical professionals, healthcare organizations and insurance providers.

In addition to Dr. Chamberlin being a respected leader in her industry, her expertise in pharmacy and operation management, compounding and dispensing of custom medications, knowledge of drug delivery methods, and product safety & quality assurance guidelines has made her a community-wide asset. Her customer service, relationship management and patient counseling only enhance her expertise and respect by all she knows, serves and counsels.

Chief Pharmacist & Co-Owner 5/2010–present
Beacon Prescriptions Compounding Pharmacy, Southington, CT

Manage ancillary staff in fulfilling more than 1400 prescriptions (> 25% custom compounded prescriptions) weekly. Consult with physicians and patients with regard to medication dosage, drug interactions, disease management and potential side effects of prescription and OTC medications.

Compound and dispense prescriptions, and maintain accurate patient records, dosing information and directions for use. Interact with prescription insurance providers concerning billing/reimbursement issues. Keep abreast of new developments within the pharmaceutical industry.

Key Contributions:

- Designed workflow for pharmacy operations for efficiency and accuracy
- Recognized for ability to manage a high volume of patient accounts
- Consulting with hundreds of physicians and patients to fill prescriptions, review side effects, discuss drug interactions and resolve medication delivery problems
- Improved drug-inventory management system to reduce waste
- Cultivated strong network of physicians
- Improved morale of coworkers by rewarding good work performance, leading by example, and providing a positive work environment

Education & Licenses

Registered Pharmacist, State of Connecticut
Doctor of Pharmacy
UConn School of Pharmacy, Storrs, CT

July 2004
May 2004



Connecticut Department of Consumer Protection
Medical Marijuana Producer License
Request for Application

Section G-1

Product and Site Safety

This page has been left blank intentionally

1347

Exhibit G1.1-2_SOP-009

Standard Operating Procedure Pest Control Program		Page 1 of 10
Document No: SOP-009	Revision: 00	

Function	Approval		Date
	Print	Signature	
Author	Peter Rafa		
Operations			
Quality Assurance			

REVISION CONTROL TABLE

Rev. #	Description of Changes	Author	Date
00	Initial Release	P. Rafa	

EXHIBIT G.1-2_SOP-009

Standard Operating Procedure Pest Control Program		Page 2 of 10
Document No: SOP-009	Revision: 00	

TABLE OF CONTENTS

PURPOSE.....	3
SCOPE.....	3
REFERENCES	3
RESPONSIBILITY.....	3
BACKGROUND.....	5
DEFINITIONS	5
PEST CONTROL PROCEDURES	5

EXHIBIT G.1-2_SOP-009

Standard Operating Procedure Pest Control Program		Page 3 of 10
Document No: SOP-009	Revision: 00	

1.0 PURPOSE

This SOP describes the process and procedural requirements of the Pest Control Program for the Theraplant facility located at 856 Echo Lake Road in Watertown, CT 06795.

2.0 SCOPE

This procedure applies to the pest control activities for the Theraplant facility.

3.0 REFERENCES

- 3.01 F-SOP-009-1 – Pest Control Record
- 3.02 F-SOP-009-2 – Pest Activity Record

4.0 RESPONSIBILITY

- 4.01 Management is responsible for:
 - 4.01.1 Monitoring the Pest Control Program and ensuring records are maintained.
 - 4.01.2 Contracting with and training the designated pest control vendor on required site procedures
 - 4.01.3 Assisting in investigation in incidences of pest intrusion inside the production facility
- 4.02 The Quality Unit is responsible for
 - 4.02.1 Conducting periodic audits of the Pest Control Program to occur at a minimum, annually
 - 4.02.2 Assisting in investigation in incidences of pest intrusion inside the production facility
- 4.03 All employees are responsible for following the procedures of the Pest Control Program.
- 4.04 The designated pest control vendor is responsible for:
 - 4.04.1 Keeping a log of all inspections and submitting this log to Theraplant Management. The logbook should have a dated facility layout mapping the location of all traps, insect lights, and glue boards
 - 4.04.2 Perform emergency visits in the case of pest sitting and infestation
 - 4.04.3 Empty, clean, and reset insect and rodent traps on a regular basis
 - 4.04.4 Providing MSDS to Theraplant for any pesticides, rodenticides, insecticides, and/or fungicides in advance of use

Standard Operating Procedure Pest Control Program		Page 4 of 10
Document No: SOP-009	Revision: 00	

4.04.5 Understanding and following this procedure when performing activities within the Theraplant production facility

Standard Operating Procedure Pest Control Program		Page 5 of 10
Document No: SOP-009	Revision: 00	

4.04.6

5.0 BACKGROUND

Manufacturing of medicinal cannabis and derivative products requires control of the production environment. Part of that control is the implementation and adherence to a Pest Control Program.

6.0 DEFINITIONS

6.01 MSDS – Material Safety Data Sheet

7.0 PEST CONTROL PROCEDURES

7.01 Background

7.01.1 Pest Control services for the Theraplant facility are performed by a licensed third-party pest control vendor and/or designated Theraplant employees.

7.01.2 All pest trap locations must be identified in Appendix 1 – Pest Control Location Diagram. They must be placed in floor locations that permit easy inspection.

7.01.3 Bait stations for rodents shall not be used inside the production facility. Bait stations may be placed outside the building if other rodent control methods are not adequate.

7.01.4 All personnel must report any observed pest activities to Management immediately using Form F-SOP-009-2, Pest Activity Record.

7.02 Formal Inspections

7.02.1 The facility will be inspected twice monthly in areas identified in Appendix 1, Figure 1.

7.02.2 Inspection will follow procedures issued by the pest control vendor.

7.02.3 The pest control vendor must complete Pest Control Record (Form F-SOP-009-1) issued by Theraplant and return it to Theraplant Management.

7.02.4 Theraplant Management to review Pest Control Record with the Quality Unit.

7.02.5 If pest activity is found in the Theraplant production facility, Management and the Quality Unit must decide on a corrective action plan. An investigation must be opened per SOP-004, “Deviations and Corrective Actions”.

Standard Operating Procedure
Pest Control Program

Page 6 of 10

Document No: SOP-009

Revision: 00

EXHIBIT G.1-2_SOP-009

Standard Operating Procedure Pest Control Program		Page 7 of 10
Document No: SOP-009	Revision: 00	

Appendix 1 – Figure 1 – Pest Control Location Diagram

NOTE – Diagram in Process

FORM F-SOP-009-1 – Pest Control Record

Page ____ of ____

Pest/Rodent Company Used* or Self	Date of Service or Action Taken	Type of Pest	Type of Control**	Location of Traps	Traps Checked (date)	Checked by (name)	Disposal Means

*If using a company for service, attach report or receipt of service for each of their visits.

Standard Operating Procedure Pest Control Program		Page 9 of 10
Document No: SOP-009	Revision: 00	

**List type of control methods used such as exclusion, traps, poison, repellants, etc.

Standard Operating Procedure Pest Control Program				Page 10 of 10
Document No: SOP-009		Revision: 00		

FORM F-SOP-009-2 – Pest Activity Record

Page ____ of ____

Location	Date	Time	Observed Pest Activity	Observed By (Print Name)

EXHIBIT G.1-2_SOP-009

Exhibit G1.1-1_SOP-002

Environmental Monitoring Program		Page 1 of 11
Document No: SOP-002	Revision: 0	

Function	Approval		Date
	Print	Signature	
Author	Peter Rafa		
Operations			
Quality Assurance			

REVISION CONTROL TABLE

Rev. #	Description of Changes	Author	Date
00	Initial Release	P.Rafa	

Environmental Monitoring Program	Page 2 of 11
Document No: SOP-002	Revision: 0

TABLE OF CONTENTS

PURPOSE.....	3
SCOPE.....	3
RESPONSIBILITY.....	3
DEFINITIONS AND ACRONYMS	4
REFERENCES AND APPLICABLE DOCUMENTS	4
MATERIALS AND EQUIPMENT	4
HEALTH AND SAFETY CONSIDERATIONS	4
PROGRAM RATIONALE AND REQUIRMENTS	5

Environmental Monitoring Program		Page 11 of 11
Document No: SOP-002	Revision: 0	

8.04.3.2 Recertification Folder

8.04.3.2.1 HEPA Filters

8.04.3.3 Filtered Water Folder

8.04.4 See Section 8.3, Out of Specification Test Response, for the reporting requirements of measurements that exceed specification.

8.05 Provisions

8.05.1 All facility/utility modifications that involve manufacturing or quality environments or modifications of shared facilities (i.e., Air Handling Systems, water systems, etc.) are subject to Change Control and must be reviewed and approved by Quality Assurance and Operations prior to the modification being performed. Review of EM policy for affected areas may be required due to such modifications.

8.05.2 Test frequencies given in this policy express minimum and not maximum testing frequency. Testing may be performed more frequently as desired or required without need for justification of the change from the schedule. However, reducing frequency of testing may only be undertaken with sufficient data and justification that the change in frequency poses minimal risk to product and consumer.



Connecticut Department of Consumer Protection
Medical Marijuana Producer License
Request for Application

Section G-2

Product and Site Safety

G.2 PRODUCT AND SITE SAFETY

Theraplant Employee Safety

Theraplant has a strong policy dictating selection criteria for choice and application of potentially unsafe chemicals such as pesticides and for PPE used when pesticides are employed. In addition, for regular production operations the Production Gowning and Personal Protective Equipment SOP (SOP-008) delineates requirements for PPE, and SOP-018, Hazard Assessment and Communication mandates hazard assessment for production operations and a clear system of communicating hazards to affected personnel.

Personal Protection Equipment

Theraplant production facility. During regular production operations, the following PPE are expected:

- Gloves – Nitrile gloves are worn in all production operations through packaging to prevent product and nutrient solution contact with employees' hands. Gloves are not required for handling product in final packaging and later stages.
- Safety Glasses – Specialty glasses made to protect from the effects of HID lamp light are worn in rooms having that lighting. Safety glasses are worn in any production operations where water is in use (including but not limited to: using and discarding nutrient solutions), and any operation where there is potential eye impact from plant material (including but not limited to: harvesting and trimming).
- Hearing Protection – Hearing protection is used in any production operation exceeding 80dB within the room of the operation.
- Facility-dedicated footwear – Any employee whose duties are primarily within the production facility will have task-appropriate footwear that does not leave the facility.

For the specific tasks of mixing and dilution of nutrient solutions and pesticides, where splashing may present a safety risk, PPE requirements will be derived first from the MSDS for the product, where available (not all nutrient solutions have MSDS). SOP-018, Hazard Assessment and Communication, delineates specific requirements for determining PPE requirements and for having occupational hazards clearly communicated within the Theraplant workplace.



Connecticut Department of Consumer Protection
Medical Marijuana Producer License
Request for Application

Section H-1

Marijuana Transport



Connecticut Department of Consumer Protection
Medical Marijuana Producer License
Request for Application

Section I-1

Employee Working Environment Plan



Connecticut Department of Consumer Protection
Medical Marijuana Producer License
Request for Application

Section I-2

Compassionate Need Plan

I.2 BONUS POINTS

Describe any compassionate need program you intend to offer. Include in your response: the protocols for determining which patients will qualify for the program; the discounts available to patients eligible for the compassionate need program; the names of other organizations with which you intend to partner or coordinate in connection with the compassionate need program, including any dispensary facility applicant; and any other information you think may be helpful to the Department in evaluating your compassionate need program.

A key part of Theraplant's mission is to be a positive force within the community. A strong compassionate needs plan is central to that mission. Due to the high priority of this mission and our commitment to regulatory compliance and efficient administration, research into best practices is ongoing with the Connecticut Pharmacists Association, social work organizations and hospice providers in the state.

- Theraplant's business model includes the allotment of 2% of medicinal marijuana products to be provided at no cost to licensed dispensaries in the state of Connecticut. This supply will be made available to those who qualify as having a debilitating illness but are economically disadvantaged.
- Effective protocols for determining which patients qualify for a compassionate need plan due to economic hardship are under study. Immediate enrollment for those who qualify for Medicaid or Supplemental Nutritional Assistance Program has been deemed too broad. Approaching the issue from an income-limit standpoint is sensible but prohibitive due to patient privacy considerations. Current practice within the Connecticut pharmacy community for providing medication at no or reduced cost to economically disadvantaged patients begin with recommendations from social service providers working with pharmacists to determine need. Theraplant's focus will be on using these established programs in order to meet the needs of this population most quickly.
- If awarded a producer license, Theraplant will reach out to all dispensaries to develop the appropriate mechanism to get Theraplant medication for the compassionate need program to patients. As a producer, Theraplant will have no direct relationship with any patients and will therefore require cooperation between producers and dispensaries to implement a successful program. The system could take the form of a rebate system to the dispensary or allocating a specified amount of subsidized medicine in each shipment to the dispensary.
- Theraplant has met with a number of hospice providers in the state of Connecticut and has committed itself to providing medication to patients who would benefit from medical marijuana in their last days. *See Exhibit I-2 - Hospice Letter.*

I.2 BONUS POINTS

- Research conducted by the Theraplant team finds that an additional process for expedited certification of terminally ill patients would need to be added to the DCP regulations in order to best serve patients in hospice care. We look forward to participating in this process.



Connecticut Department of Consumer Protection
Medical Marijuana Producer License
Request for Application

Exhibits to Section I-2

Compassionate Need Plan



159 Nunzio Drive
Plantsville, CT 06479
<http://www.theraplant.co>
Organic Medical Therapy™

To Hospice Centers in Connecticut:

End of life care and treatment is something that Theraplant, a manufacturer of medical marijuana, is committed to. We would propose a compassionate care model in which we provide your hospice facility with our products at little or no cost. As with any medication, the medical marijuana would have to be provided with a doctor's certificate and regulated by the DCP. The type of product would be reflective of the symptoms the patient is suffering from. People at this stage of life need any medication that could help readily available.

Theraplant wants to make this commitment to your facility, the DCP and the people of Connecticut by creating a specialize program within the oversight of each hospice center and the physicians that oversee the facility.

Connecticut's well constructed regulatory system works for 99% of our population, however it does not provide the ability for immediate access to medical marijuana as an option for terminally ill patients. Working with your facility and your association we would work with the Department of Consumer Protection (DCP) to create a system that would allow hospice patients' immediate access to medicinal marijuana to assist in the compassionate care of all patients. Many of the current medications are derived from opiates and these products often result in debilitating side effects and reduce quality of life.

Theraplant has committed itself to scientifically identify the key components of the plant that would best be suited for hospice treatment. Studies confirm that there is no risk of a lethal dose of marijuana. Additionally, recent research suggests the efficacy of specific chemicals in marijuana directly correlate to better sleeping patterns and increased appetite.

Working with DCP and hospice we hope to ensure end of life patients are given the best and safest opportunity for treatment. We owe it to our elders and this compassionate care is of paramount importance to me personally.

Thank you for your time, we look forward to working together on this important issue.
Sincerely,

Ethan Ruby

President
Theraplant, LLC



Connecticut Department of Consumer Protection
Medical Marijuana Producer License
Request for Application

Section I-3

Research Plan



Connecticut Department of Consumer Protection
Medical Marijuana Producer License
Request for Application

Exhibits to Section I-3

Research Plan



November 15, 2013

To Whom It May Concern:

The purpose of this letter is to inform the State of Connecticut Department of Consumer Protection(DCP) that the **Connecticut Pharmacists Association (CPA)**, a 501(c)6 professional organization representing pharmacists in the State of Connecticut since 1876, will be conducting a Research Monitoring Program in the State of Connecticut related to the medicinal use of cannabis.

It is the intent of the CPA to partner with the **Canadian Consortium for the Investigation of Cannabinoids (CCIC)** in order to conduct this proposed research monitoring program with the marijuana growers and dispensaries that receive licenses from the State of Connecticut. CCIC is a federally registered Canadian nonprofit organization of basic and clinical researchers and health care professionals established to promote evidence-based research and education concerning the endocannabinoid system and therapeutic applications of endocannabinoid and cannabinoid agents.

Please note that Therplant, the subject of this application, has committed to the CPA that it will financially support this Research Plan and study initiative if their company is selected by the State of Connecticut to grow and produce medical cannabis.

The Research Plan will be designed independently by CPA and CCIC after soliciting input from, and working with, the DCP, growers, dispensaries and other stakeholders.

The objectives will be to quantify the doses and modes of the cannabis administration and to explore the associations between cannabis products and patient phenotypes. At this time, it is not known how long a study such as this will take to complete.


In general, the overall goal will be to systematically collect long-term data on the safety and efficacy of herbal cannabis used for medical purposes. What makes this study unique is that with this **international collaboration**, data collection from each country can be compared and studied to provide a very in-depth analysis and outcomes summary.

It is our estimation that the results and data gleaned from the study will be used to inform policy-makers and regulatory agencies about safety aspects of medical cannabis; clinicians will be better informed about best practice guidelines and safety issues, and the medical cannabis producers will receive beneficial information about the efficacy of their products in real world situations. Most importantly, due to how the

Connecticut regulations are written, the pharmacists, who are an integral piece to both the data collection and dispensing activities, will have a comprehensive and data driven approach when educating patients about their medical use of cannabis.

The CPA has a strong and positive history of working with state agencies, universities and the pharmacists we represent in programs that involve both pharmacists and patient outcomes. It is due to this synergy and focus that the CPA feels that it is well-positioned to be the critical component to ensure that the Research Plan reflects the highest quality evidence-based "best practices" and continuing education for all those involved in this, emerging sector of patient care in Connecticut.

Sincerely,



Margherita R. Giuliano, RPh
Executive Vice President
Connecticut Pharmacists Association



Mark A. Ware MD MSc
Executive Director
Canadian Consortium of the Investigation of Cannabinoids



To whom it may concern,

I have been in contact with Ethan Ruby, the founder of Theraplant LLC. I was informed that this company will be responding to the Department of Consumer Protection's Request for Applications. My understanding is that this company is focused on the science of medical marijuana and that they would like to pursue research and development including clinical trials, patient studies and plant science. Theraplant reached out to me because of my role as a professor of horticulture at the University of Connecticut and has asked for my personal assistance and advice in the area of plant science. My particular expertise is in the area of controlled environmental plant production. Since Theraplant is focused on the science of medical marijuana in the context of Connecticut's exemplary legal approach to pharmaceutical use, I view this as a unique and exciting opportunity.

I understand the current DEA regulatory environment has tight controls on research in this field that may create initial obstacles for the University of Connecticut to engage in sponsored research agreements, but look forward to eventually having the opportunity to be involved in cutting edge plant science.

Sincerely,



George C. Elliott, Ph.D.
Associate Professor of Horticulture
Department of Plant Science and Landscape Architecture
University of Connecticut
1376 Storrs Road Unit 4067
Storrs, CT 06269-4067

Gaylord Specialty Healthcare

300 Park Ave.
Old Saybrook, CT
Wethersfield, CT
860-522-1000
860-522-2000 (fax)
www.gaylord.org

October 15, 2013

Mr. Ethan Ruby
1265 South Corona Street
Denver, CO 80210

Dear Mr. Ruby:

Thank you for your visit to Gaylord Hospital and taking the time to explain your background, experience and vision. As a long term acute care hospital that takes care of many of Connecticut's rehabilitation patients, we recognize the potential for medicinal marijuana in alleviating the suffering of many of our patients. Although traditional in our approach to the use of some therapies, we have recently been very progressive in our use of robotic technology to help in alleviating muscle spasticity in our paraplegic patients. After careful review of the literature, we feel that this view should be extended to a discerning use of medicinal marijuana as well.

We were impressed at the time of your visit with your company's clear focus on patient-centered opportunities regarding not only medicinal marijuana, but continued support, education and programs. We are open to consideration of research projects and potential collaboration. We appreciate your sensitivity to the financial constraints of many of the citizens of our state and welcome your intention to provide some financial support for those qualified and clinically appropriate for treatment but without the funds to obtain the medication.

We look forward to educational programming for staff, and would welcome co-sponsorship with Theraplant programs as appropriate. If you do get the grant, we look forward to collaboration with you and Theraplant in furthering our care of this patient population.

Sincerely,



David S. Rosenblum, M.D.
Medical Director, Rehabilitation

DSR:smf



Connecticut Department of Consumer Protection
Medical Marijuana Producer License
Request for Application

Section I-4
Community Benefits Plan

4. Community Benefits Plan: Provide the Department with a detailed description of any plans you have to give back to the community either at a state or local level if awarded a producer license.

As recognized by Senator Robert Kane, R-32, in his letter to the DCP recommending approval of Theraplant's application, "Theraplant's CEO is a disabled individual who is fully committed to giving back to our community and state" (*See Senator Kane letter Exhibit I-4-1*). As demonstrated by the fact that Theraplant has been active in the community for the past nine months leading up to the submission of the application, through sponsorship of the Connecticut Police Chief's Association golf tournament or Moving With Hope's annual Greenway Bike Challenge and Music Festival, Theraplant's commitment to positive community involvement begins well in advance of approval and will continue well beyond (*See Chief Gavallas letter Exhibit I-2 and Mr. Duni's letter Exhibit I-4-2*). The following are some preliminary plans.

- Ethan Ruby has a long and impressive record of fund-raising and life-improving pursuits for the disabled, particularly those with spinal cord injury such as *himself* (*See Ethan Ruby Resume Exhibit E-2 and Buoniconti letter Exhibit I-4-3*). In that spirit, Theraplant has established a mutually beneficial partnership with the State of Connecticut Department of Rehabilitative Services to establish an Industry Specific Training and Placement Program to provide "Connecticut citizens with disabilities the opportunity to learn cutting-edge work skills in a newly established industry." (*See Commissioner Porter letter Exhibit I-4-4*).
- In addition, Theraplant will reserve at least 2 jobs within the facility specifically for disabled individuals and will work with a local non-profit to identify ideal candidates.
- Structured opportunities for Theraplant employees to volunteer within the community as part of their job responsibilities, such as company-wide volunteer days or paid time off to participate in volunteer projects, are under development.
- Theraplant will set aside \$10,000.00 initially to establish a grant fund to which small, local organizations can apply to fund their activities.
- The complete interior and exterior renovation of the now empty building that will become the Theraplant manufacturing facility will improve surrounding property values.
- Theraplant will take advantage of Rideworks consultation services to create a customized transportation managements plan to help our company promote alternatives to driving to work alone to our employees. Rideworks is a Connecticut-based non-profit that promotes environmentally friendly transportation options.

I-4 Bonus Points

- Upon award of the producer license, Theraplant will join the local Chamber of Commerce and take necessary steps to become a member in good standing.
- Please refer to letter from Joseph Seacrist, Economic Development Coordinator for the town of Watertown, Connecticut for the inception of Theraplant's community involvement from the perspective of a local official (*See Seacrist letter Exhibit A3-3*).



Connecticut Department of Consumer Protection
Medical Marijuana Producer License
Request for Application

Exhibits to Section I-4

Community Benefits Plan



State of Connecticut

SENATE

STATE CAPITOL
HARTFORD, CONNECTICUT 06106-1591

SENATOR ROBERT J. KANE
THIRTY-SECOND DISTRICT

LEGISLATIVE OFFICE BUILDING
SUITE 3400
HARTFORD, CONNECTICUT 06106-1591
Capitol: (860) 240-8875
Toll Free: (800) 842-1421
E-mail: Rob.Kane@cga.ct.gov
Website: www.SenatorKane.com

DEPUTY MINORITY LEADER PRO TEMPORE AND
CAUCUS CHAIRMAN FOR POLICY

RANKING MEMBER
APPROPRIATIONS COMMITTEE

MEMBER
PUBLIC HEALTH COMMITTEE
REGULATIONS REVIEW COMMITTEE

Commissioner William Rubenstein
Department of Consumer Protection
165 Capitol Avenue
Hartford, Connecticut 06106

October 17, 2013

Commissioner Rubenstein,

As the state senator representing the Town of Watertown, I have had the opportunity to meet with the principals of Theraplant LLC over the last few months. While the policies governing medical marijuana still give me some pause, Theraplant has been an example of the right way to cultivate this industry. My personal interactions with Theraplant and the town leadership lead me to believe that they are a professional and responsible business committed to producing a safe, secure and uninterrupted supply of this pharmaceutical product.

Additionally, Theraplant's CEO is a disabled individual who is fully committed to giving back to our community and the state. The manufacturing facility will be fully accessible and the company has committed to hire disabled individuals to work in the facility. They are in discussions with the Bureau of Rehabilitation Services to be a training site for the state and have discussed partnering with several of the state's non-profits to help the disability community.

I expect Theraplant to meet or exceed all the requirements in your RFA and when that happens I will feel comfortable in recommending that Theraplant receive one of the three licenses that DCP will award. Due to their strong business model, strict and extensive security procedures, and transparent relationship with both state and local representatives I support Theraplant to do business in my district.

I ask the Department of Consumer Protection to approve their application.

Sincerely,

A handwritten signature in black ink, appearing to read "R. J. Kane".

Rob Kane
Deputy Minority Leader Pro Tempore

DEPARTMENT OF POLICE
195 FRENCH STREET
WATERTOWN, CT 06795
TELEPHONE #: (860) 945-5200
FAX #: (860) 945-2642

John C. Gavallas
Chief of Police

Robert J. Desena
Deputy Chief of Police

September 19, 2013

To Whom It May Concern:

Re: Theraplant Company Application

I am writing this letter on behalf of Ethan Ruby, whom has a pending application to open a medical marijuana production facility in the Town of Watertown, Connecticut.

As police chief of Watertown, I have had the opportunity to meet with and discuss with Mr. Ruby and his staff their plans for this facility.


Obviously, my immediate concern is centered around plant security. After meeting with Mr. Ruby personally on two occasions and having several conversations with him regarding this subject, it is apparent to me that the safety of the employees and a well thought out plan for securing the facility, which includes 100 percent video monitoring, is at the forefront of this endeavor.

Through my interaction with Mr. Ruby and his staff, I feel confident in attesting to his good character and sincerity in being totally transparent in all phases of this project with me as well as all other town officials.

I am confident Mr. Ruby will be a great corporate partner with the Watertown community, and I look forward to working closely with him and his staff as this project becomes a reality.

If I can be of any further assistance regarding this matter, please do not hesitate to contact me.

Sincerely,


John Gavallas
Chief of Police

JG:pg

cc: Charles Frigon, Town Manager

A State Accredited Law Enforcement Agency



415 Howe Avenue, Suite 104
Shelton, CT 06484
203-513-8424

October 3, 2013

Dear Ethan,

This communication is meant as a formal understanding of the work of MovingWithHOPE, Inc., a non-profit 501(c)3 organization located in Shelton, CT.

MovingWithHope, Inc., (MWH) was founded in 2010 with a mission to improve the quality of life for people with moderate to severe brain, spine and orthopedic injuries. MWH accomplishes this through a scholarship to year-round post-acute activity therapy and nutrition education programs. For the first time since their injury, our clients make remarkable progress with gains in balance, mobility and general health. Theraplant, I believe, has a very similar mission.

Over the past 4 years, MWH has developed significant partnerships with agencies and organizations in Connecticut; the Valley Community Foundation in funding of our awareness and educational programs, the National Spinal Cord Injury Association, CT Chapter in the purchase of equipment; the Obie Harrington-Howes Foundation with grants to help folks with spinal injuries and diseases receive access to our programs or to purchase and repair specialized equipment. As a group, we are also very involved with the Lower Naugatuck Valley Chamber of Commerce, Valley Substance Abuse Council, and the Health and Human Services Council.


MWH has developed several programs and fundraisers that help provide scholarships for our clients, but none more important than our annual Greenway Bike Challenge and Music Festival held in September in Shelton, CT. With Theraplant as a major sponsor with \$5,000 in financial support, our goal of raising \$75,000 will be in sight. These funds would create dozens of scholarships, and provide equipment and accessories needed to support even better client outcomes.

Of course, this relationship is contingent on Theraplant's successfully obtaining a license from the DCP. To that end, if I might suggest Theraplant choose our organization, one with such dedication to community.

On behalf of the board of directors of MovingWithHOPE, I look forward to a long and successful partnership with Theraplant.

A handwritten signature in black ink, appearing to read "Tad Duni".

Sincerely,
Tad Duni
President and Founder
MovingwithHOPE, Inc.



October 1, 2013

Department of Consumer Protection of Hartford, Connecticut
Hartford, Connecticut 06106

To Whom It May Concern:

It is with great enthusiasm that I write this letter of recommendation for Ethan Ruby.

I have known Ethan, personally and professionally, for 13 years. He is a man of integrity with excellent work ethics, who has dedicated over 11 years to helping us raise awareness and funds for our foundation, The Buoniconti Fund to Cure Paralysis.

Ethan accepted the role as the Volunteer Director of the New York Chapter of The Buoniconti Fund, organizing multiple charity events each year, for 5 years. The creator of the Poker4Life Charity Poker Tournament, whose hard work and dedication has made this a very successful event. In 8 years of existence, The Poker4Life Charity Poker Tournament has raised and contributed over \$1m towards research.

His passion to help others, specifically in the disabled community, is very well mirrored when he speaks at the annual Poker4Life Tournament as well as, at the many other public speaking appearances and engagements in which he participates.

Ethan's invention and production of the WheelComfort Padded Footplate is yet another reflection of his great work and determination to make a difference. This great product has brought comfort and protection to many wheelchair users.

It goes without saying, that Ethan's commitment to the disabled community and to doing charitable work clearly voices his soaring internal motivation.

I highly recommend Ethan and I hope you agree that he would be an excellent candidate.

Sincerely,

President

(305) 243-7157 Office
mbuoniconti@umiami.edu

PHYSICAL ADDRESS: 1095 NORTH WEST 14TH TERRACE, MIAMI, FLORIDA 33136 • 305-243-6001 FAX 305-243-6017

MAILING ADDRESS: POST OFFICE BOX 016960, MAIL LOCATOR R-40, MIAMI, FLORIDA 33161

WWW.THEBUONICONTIFUND.COM • INFO@MIAMIPROJECT.MED.MIAMI.EDU



STATE OF CONNECTICUT
DEPARTMENT OF REHABILITATION SERVICES

October 7, 2013

To Whom It May Concern:

The Department of Rehabilitation Services has been engaged in preliminary discussions with Theraplant and its founder, Ethan Ruby, to assist in diversifying their workforce by including employees with disabilities. One possibility for their facility is an Industry Specific Training and Placement Program. These training programs are designed to suit specific occupations and careers while utilizing the principles of Universal Design to increase the training program's overall accessibility and potential for success. Training would be provided to develop the skills required for employment in a particular career and to place successful participants on a career path leading to long-term employment stability.

This mutually beneficial partnership would provide Connecticut citizens with disabilities the opportunity to learn cutting-edge work skills in a newly established industry. This partnership would also provide a trained, talented and diverse workforce to eventually be employed at Theraplant.

We realize that such a partnership is contingent on Theraplant successfully receiving a license to operate from the State of Connecticut. The Department of Rehabilitation Services looks forward to this venture and all of the potential it brings for the citizens of Connecticut.

Respectfully,

A handwritten signature in blue ink that reads "Amy Porter".

Amy Porter
Commissioner
Department of Rehabilitation Services



September 13, 2013

To Whom it May Concern

Re: Theraplant Company Application for a Medical Marijuana Production Facility in Watertown CT.

This is a letter of support for the application of the Theraplant Company to open a medical marijuana production facility in the Town of Watertown, Connecticut.

Mr. Ethan Ruby, the Company President and his whole management team requested a series of meetings with various Town of Watertown officials well before he proceeded with a formal application to the Planning and Zoning Commission, in order to make sure he and his company would be welcome in Watertown. After a number of such meetings, on behalf of the Town, I assured him his business will be well regulated not only by the Town but by state regulations, and as such he, his team and his business were welcome in the Town.

In addition, I performed due diligence on Mr. Ruby and his personal and professional history. After a thorough internet search, it became clear that Mr. Ruby was not just a responsible businessman, but a significant contributor to many charitable causes in support of other paraplegics, since Mr Ruby is himself a paraplegic and confined to a wheelchair.

Above and beyond his stellar personal background, Mr. Ruby and his team have proven themselves to be competent and ethical business people. They have eagerly and willingly met with all Town regulators and elected officials, filed all paperwork on time without complaint, met personally before our Planning and Zoning Commission as well as our Economic Development Commission. They were eager to have public forums in which possibly concerned citizens could voice their opposition. To date, only three

citizens have expressed concerns to me, which is highly unusual for the Town of Watertown, where citizens frequently turn out in large numbers to voice their opinions.


Mr. Ruby has indicated that he and his team plan to relocate their personal families and homes in the Watertown community, showing personal support for the longevity and permanence of their proposed business.

Theraplant has an option to purchase an approximately 64,000sf former industrial paint factory in our business park pending the approval of their application. My research indicates that a smaller sized building would probably not be able to meet the stringent standards of the Department of Consumer affairs' regulations for such a facility. The neighboring companies in the Business Park have welcomed the addition of the company.

Mr. Ruby has already spent several hundreds of thousands of dollars on building plans for the proposed facility, security plans for the facility, and has voluntarily met with our Police Chief and Fire Chief on several occasions to get their approval of the fire and security plans for the facility. Both Chiefs are pleased and satisfied with Theraplants's response to their questions.

In short, the Town of Watertown and the Economic Development Commission wholeheartedly welcomes and supports the application of Theraplant Company to build a medical marijuana growing facility and become an active member of the Watertown business community.

Sincerely,



Joseph Seacrist
Economic Development Coordinator
Town Hall Annex, 424 Main Street
Watertown CT 06795
(860) 945-4858
e-mail: Seacrist@watertownct.org

CC: Charles Frigon, Town Manager
Joseph McGrail, Chairman Watertown Economic Development Commission



Connecticut Department of Consumer Protection
Medical Marijuana Producer License
Request for Application

Section I-5

Substance Abuse Prevention Plan

I.5 Bonus Section

Substance Abuse Prevention Plan: Provide a detailed description of any plans you will undertake, if awarded a producer license, to combat substance abuse in Connecticut, including the extent to which you will partner, or otherwise work, with existing substance abuse programs.

Substance Abuse Programs

- Theraplant will partner with experienced Connecticut professionals in the substance abuse area, to develop specific content to educate patients and the community at large on medical marijuana issues.
- Southeastern Council on Alcoholism and Drug Dependence, Inc., has agreed to partner with Theraplant to develop materials to both educate patients and the public on the proper use of medical marijuana, and prevent the abuse of marijuana and other prescription drugs

See Exhibit I-5 letter_SCADD

- Michael Anthony's Project, has agreed to partner with Theraplant to develop a campaign, including printed materials and a series of presentations to local schools, highlighting the negative aspects of non-medical marijuana use.

See Exhibit I-5 letter_MAP



Connecticut Department of Consumer Protection
Medical Marijuana Producer License
Request for Application

Exhibits to Section I-5

Substance Abuse Prevention Plan



Southeastern Council on Alcoholism and Drug Dependence, Inc.

Compassion

November 5, 2013

Support

To Whom It May Concern:

Comfort


The Southeastern Council on Alcoholism and Drug Dependence, Inc. (SCADD) is an organization dedicated to helping people and their families with alcohol and substance abuse problems. We have met with and signed a letter of intent to create, update and monitor a substance abuse and prevention program for Theraplant, LLC. Theraplant is currently in the process of applying to be one of the state's first licensed medical marijuana producing facilities in Watertown Connecticut. Our discussions with the Principals of Theraplant have made it clear to me the company is committed to maintaining the integrity of medical marijuana by emphasizing the medical research side of the business and being a good corporate citizen by developing a strong outreach and public education program about medical marijuana, its uses and preventing its abuses.

Empowerment

Recovery

SCADD has followed closely and viewed cautiously the introduction of a medical marijuana industry in Connecticut and will continue to monitor its development. We also feel it necessary and important to be situated closely so that substance abuse best practices we have developed and endorse are available to those venturing into this new field. It is in that spirit this collaboration originates. Through our experience in providing substance abuse treatment throughout Eastern Connecticut for the past 47 years we will be helping Theraplant educate the public and their patients about the proper use of marijuana and preventing the abuse of this and any other prescription drug. It is our vision that this education process will be integrated with patient treatment. We are working with Theraplant to tailor a program that will promote the correct use of medical marijuana, which will ultimately lead to the safest and most effective treatment.

Theraplant has shown that it truly cares about the consumer and the science of medical marijuana. Promoting the correct use of medicinal marijuana is in alignment with the core values of both Theraplant and SCADD. Consequently, we will continue to aid Theraplant in constructing substance abuse prevention policies by making our resources available to them.

Sincerely,

John F. (Jack) Malone

President and Executive Director
Southeastern Council on Alcoholism and
Drug Dependence, Inc.
S.C.A.D.D.

Michael Anthony's Project, INC

619 Guernseytown Road

Watertown, Ct 06795

10-29-2013

Dear Mr. Ruby,

It was a pleasure speaking to you and agree upon a partnership with Theraplant to prevent substance abuse throughout the State of Connecticut. Michael Anthony's Project INC, a non-for profit organization dedicated to providing support, education and resources to those suffering from the disease of addiction, as well as to their families and loved ones, shares your belief: Preventing a problem is better than dealing with it well. Our principle that it takes a village to raise a child has lead us to form cohesive relationships with city and state officials as well as health care providers to help stop addiction before it begins. In this regard, please accept this letter of intent should you be selected for a Medical Marijuana Production Facility License by the State of Connecticut.

Michael Anthony's Project looks forward to the proposed partnership with Theraplant to assist in executing a new substance abuse prevention plan. Preventing abuse of marijuana clearly requires an updated message. The new Medical Marijuana regulations in our state create a need for awareness that this, like any medication, should be treated very carefully. We will work with Theraplant to create a campaign, including printed materials and a series of presentations to students' local schools that highlights the negative aspects of recreational marijuana use. Our substance abuse prevention professionals would employ all of the latest research and would solicit input from students, teachers, parents and others within the community to craft the most effective messaging for our target audience.

We understand that our work together on this very important endeavor is contingent upon your selection by the Department of Consumer Protection as a medical marijuana producer in the state of Connecticut and, therefore, we highly recommend your approval by DCP. I'm sure I speak for substance abuse agencies statewide when I tell you how much we appreciate your efforts in getting out ahead of the potential issues that the legalization of medical marijuana creates from a substance abuse standpoint.

Sincerely,

Lori Pelosi

Lori Pelosi, Founder

Michael Anthony's Project, INC

Lori Pelosi



Connecticut Department of Consumer Protection
Medical Marijuana Producer License
Request for Application

Section I-6


Environmental Plan



Connecticut Department of Consumer Protection
Medical Marijuana Producer License
Request for Application

Exhibits to Section I-6

Environmental Plan



Theraplants, LLC
Solar Proposal

Greenskies 



TABLE OF CONTENTS

3	Cover Letter
4	PPA Terms
5	Exhibit A
6	Exhibit B
7	Proposed Site
8	Technology
18	Conclusion


Mr. Ruby,

It is with great pleasure that Greenskies Renewable Energy LLC presents to Theraplants, LLC this proposal is for the installation of a Solar Array at Therplant's facility in Watertown, Connecticut.

Greenskies maintains an exclusive focus on solar energy and executes Power Purchase Agreements ("PPAs") and Solar Installation Agreements ("SIAs") throughout New England and the Mid-Atlantic. Every ounce of our company is dedicated to designing, engineering, financing, constructing and maintaining solar projects like the one described herein. What makes Greenskies surpass the competition is simple: a formidable combination of solar-specific expertise, financial commitment and proprietary value-added components such as contract modeling, online billing and creative deal structuring.

This proposal describes the PPA option. It contains a description of the power plant, the financial parameters, and some of the contract terms. Most importantly, this proposal explains how to shape a relationship that will allow Theraplants, LLC to begin saving and enjoying the benefits of our comprehensive energy solutions ahead of the curve. Thank you for your time in reviewing this. I look forward to meeting with you.

Sincerely,



Andrew Chester, Vice President

In a Power Purchase Agreement, Theraplants, LLC agrees to purchase 100% of the energy produced by the Solar Array. All responsibilities concerning the Array shall be borne by Greenskies Renewable Energy, LLC and its affiliates. General descriptions of the terms of the PPA are found below.

The business terms set forth herein have been created with the underlying assumption that Greenskies Renewable Energy, LLC, its affiliates and or its assigns will install, service, maintain, and monitor a Solar Array ("Array") owned by a Special Purpose Entity ("SPE") on certain property owned by Theraplant, LLC ("Project").

1. PROPERTY

That certain property owned by Theraplants, LLC – 856 Echo Lake Road, Watertown, Connecticut ("Property").

2. INSTALLATION

Greenskies will install on the Property a 700,000 kilowatt ("kW") ground and roof-mounted system. Greenskies will be responsible for properly engineering the Array and the installing of the same to the Property. Prior to installation, Greenskies will acquire approval from all appropriate state, utility and municipal committees and institutions for permitting, net-metering and grid-interconnection purposes.

3. PPA

Theraplants, LLC will enter into a PPA with an SPE to contractually obligate Theraplants, LLC to purchase 100% of the electricity produced by the Array. The SPE will sell to Theraplants, LLC all electricity produced by the Array during the term of the PPA, at the price per kilowatt-hour specified in Exhibit A - PPA.

Exhibit A - PPA (on page 5) — To determine the price per kilowatt-hour under this exhibit, the solar rate is set at \$0.10/ kWh. The price will escalate by 2% each year for the Term of the PPA allowing Theraplants, LLC the maximum amount of price security and predictability. Exhibit A - PPA assumes a 4% rate of inflation on conventional energy costs over a 20-year period. As conventional electricity costs out-inflate the 2% solar escalator, the savings experienced by Theraplants, LLC accelerates.

Exhibit B (on page 6) — Describes the technical assumptions made and the sources used to create Exhibit A - PPA.

4. TERM

The initial term of the PPA shall be for 20 years. Following the conclusion of year five (5) of the PPA, Theraplants, LLC shall be provided with an option to purchase the Array from the SPE at a price and upon terms which are to be determined in the PPA. After the 20-year initial term Theraplants, LLC will have the option of: (a) purchasing the Array at fair market value; (b) extending the PPA for an additional 5 years; or (c) requesting Greenskies to remove the Array.

5. PPA CONTINGENCIES

The performance of Greenskies' responsibilities under the terms of the PPA shall be subject to the following contingencies:

- Acceptance by the local power company of a utility interconnect
- SPE to acquire requisite state-level incentives in applicable EDC territory
- Approval of the Project by all applicable state, local and federal permitting authorities.

6. DELIVERY

The Array shall be live and online within 365 days of the acquisition of state-level incentives. Upon actual delivery, Theraplants, LLC shall become immediately responsible for the payment of the price per kilowatt-hour of the electricity generated by the Array as it is commissioned by appropriate state and utility authorities.

7. GREENSKIES' CONTINUING RESPONSIBILITIES

It shall be the ongoing responsibility of the SPE and Greenskies during the entire Term of the PPA, to repair, service, maintain and monitor the Array. Such services shall be at no cost to Theraplants, LLC, who has only a responsibility to purchase the electricity produced by the Array at the agreed-upon rate. The SPE will also provide Theraplants, LLC with online, real-time monitoring of the electrical generation of the Array for the term of the PPA.



	Solar Output with 0.50% Degradation Factor	Solar Electricity Cost	Estimated Utility Rate with 4.0% Escalation Factor	Rate Savings (Current Utility rate minus Solar rate)	Savings with Solar
Year	Solar kWh/Year	\$/kWh	\$/kWh	\$/kWh	
1	972,814	0.100	0.166	0.066	\$64,206
2	967,950	0.102	0.173	0.071	\$68,376
3	963,110	0.104	0.180	0.076	\$72,720
4	958,295	0.106	0.187	0.081	\$77,245
5	953,503	0.108	0.194	0.086	\$81,957
6	948,736	0.110	0.202	0.092	\$86,863
7	943,992	0.113	0.210	0.097	\$91,970
8	939,272	0.115	0.218	0.104	\$97,286
9	934,576	0.117	0.227	0.110	\$102,819
10	929,903	0.120	0.236	0.117	\$108,576
11	925,253	0.122	0.246	0.124	\$114,566
12	920,627	0.124	0.256	0.131	\$120,797
13	916,024	0.127	0.266	0.139	\$127,279
14	911,444	0.129	0.276	0.147	\$134,020
15	906,887	0.132	0.287	0.156	\$141,030
16	902,352	0.135	0.299	0.164	\$148,319
17	897,840	0.137	0.311	0.174	\$155,898
18	893,351	0.140	0.323	0.183	\$163,776
19	888,884	0.143	0.336	0.193	\$171,964
20	884,440	0.146	0.350	0.204	\$180,475
Total	18,559,252	0.121	0.247	0.126	\$2,310,142




EXHIBIT B

	Technical Assumptions	Sources
Solar Output	972.814 kWh/Year	National Renewable Energy Laboratory; System Advisor Model (SAM); SAM simulates solar electrical production by utilizing many variables including geographic location and system design parameters
Average Commercial Utility Rate	\$0.166/kWh	Price per kWh determined from Thetaplants, LLC generation, transmission and distribution costs.
Utility Inflation	4.00%	In a ten-year span (1999 - 2009) the Office of Legislative Research found an average inflation rate of approximately 5.70%. See, McCarthy, Kevin E., <i>Connecticut's High Inflation Rates and the Legislative Response</i> , 2010. http://www.cga.ct.gov/2010/rpt/2010-R-0015.htm
Solar Degradation Rate	0.50%	The National Renewable Energy Laboratory, a National Laboratory of the U.S. Department of Energy produced a comprehensive report in 2011 demonstrating solar degradation rates. Jordan D.C., Smith R.M., Osterwald C.R., Gelak E., Kurtz S.R. <i>Outdoor PV Degradation</i> , Conference Paper NREL/CP-5200-47704, February 2011.

PROPOSED SITE



Site Address Theraplants, LLC, 856 Echo Lake Road, Watertown, CT 06795
Type of Solar Array Ground Mount, Roof Mount
Approximate Area 155,000 sq. feet (3.6 Acres)
Array Size 700 KW





TECHNOLOGY


YGE 72 CELL SERIES

YL300P-35b
YL295P-35b
YL290P-35b
YL285P-35b
YL280P-35b

NEW!



U.S. Soccer Powered by Yingli Solar



COMPANY

Yingli Green Energy (NYSE:YGE) is one of the world's largest fully vertically integrated PV manufacturers. With over 3.6 GW of modules installed globally, we are a leading solar energy company built upon proven product reliability and sustainable performance. Founded in 1998, Yingli Green Energy serves customers through our U.S. subsidiary, Yingli Americas, co-headquartered in New York and San Francisco. We are the first renewable energy company to sponsor the U.S. National Soccer teams and the FIFA World Cup™.

PERFORMANCE

- Industry leading in-house manufacturing of polysilicon, ingots, wafers, cells and modules ensures tight control of our material and production quality.
- High performance, multicrystalline solar cells deliver a module series efficiency of up to 15.4%, reducing installation costs and maximizing the kWh output per unit area.
- Tight positive power tolerance of -0W to +5W ensures modules are delivered at or above rated power, improving system performance through the reduction of module mismatch loss.

QUALITY & RELIABILITY

- Robust, corrosion resistant aluminum frame independently tested to withstand wind and snow loads of up to 50 psf and 113 psf, respectively, ensuring mechanical stability.
- Manufacturing facility certified to ISO9001 Quality Management System standards.
- Module packaging optimized to protect product during transportation and minimize on-site waste.

WARRANTIES

Leading limited power warranty* ensures 91.2% of rated power for 10 years, and 80.7% of rated power for 25 years.

- 10-year limited product warranty.

*In compliance with our warranty terms and conditions.

QUALIFICATIONS & CERTIFICATES

UL 1703 and ULC 1703, UL Fire Safety Class C, CEC, FSEC, ISO 9001:2008, ISO 14001:2004, BS OHSAS 18001:2007, SA8000



YINGLISOLAR.COM/US | Yingli Americas



*Final equipment selections based on engineered analysis and market conditions. Greenskies reserves the right to use the equipment described here or an approved equal.



YGE 72 CELL SERIES

Powered by YINGLI

ELECTRICAL PERFORMANCE

Electrical parameters at Standard Test Conditions (STC)

Module type		YL300P-35b	YL295P-35b	YL290P-35b	YL285P-35b	YL280P-35b
Power output	P _{max} W	300	295	290	285	280
Power output tolerances	ΔP _{max} W			-0/+5		
Module efficiency	η _m %	15.4	15.1	14.9	14.6	14.4
Voltage at P _{max}	V _{mppt} V	36.7	36.3	35.8	35.5	35.5
Current at P _{max}	I _{mppt} A	8.17	8.12	8.10	8.02	7.89
Open-circuit voltage	V _{oc} V	46.3	45.4	45.3	45.0	45.0
Short-circuit current	I _{sc} A	8.77	8.63	8.62	8.50	8.35

STC: 1000W/m² irradiance, 25°C cell temperature, AM 1.5g spectrum according to EN 60904-3
 Average relative efficiency reduction < 5.0% at 200W/m² according to EN 60904-1

Electrical parameters at Nominal Operating Cell Temperature (NOCT)

Power output	P _{max} W	217.3	214.2	210.6	207.7	203.3
Voltage at P _{max}	V _{mppt} V	33.4	32.7	32.3	32.0	32.0
Current at P _{max}	I _{mppt} A	6.51	6.55	6.53	6.46	6.36
Open-circuit voltage	V _{oc} V	42.7	41.4	41.3	41.1	41.1
Short-circuit current	I _{sc} A	7.10	6.99	6.98	6.89	6.76

NOCT: open-circuit module operation temperature at 800W/m² irradiance, 20°C ambient temperature, 1 m/s wind speed

THERMAL CHARACTERISTICS

Nominal operating cell temperature NOCT °C	46 +/- 2
Temperature coefficient of P _{max} y / °C	-0.45
Temperature coefficient of V _{oc} β _{oc} / °C	-0.33
Temperature coefficient of I _{sc} β _{sc} / °C	0.06
Temperature coefficient of V _{mppt} β _{mppt} / °C	-0.45

OPERATING CONDITIONS

Max. system voltage	600Vcc
Max. series fuse rating	15A
Limiting reverse current	15A
Operating temperature range	-40 to 194°F (-40 to 90°C)
Max. static load, front (e.g., snow and wind)	113 psf (5400 Pa)
Max. static load, back (e.g., wind)	50 psf (2400 Pa)
Hailstone impact	1 in (25 mm) at 51 mph (23 m/s)

CONSTRUCTION MATERIALS

Front cover (material/type/thickness)	Low iron glass / tempered / 4.0 mm Glass may have anti-reflective coating
Cell (quantity/material/type/dimensions/area/# of busbars)	72 / polysilicon / multicrystalline / 156 mm x 156 mm / 243.3 cm ² / 2 or 3
Encapsulant (material)	Ethylene vinyl acetate (EVA)
Frame (material/color)	Anodized aluminum alloy / silver
Junction box (protection degree)	IP65
Cable (type/length/gauge/inside diameter)	PV Wire / 47.24 in (1200 mm) / 12 AWG / 0.244 in (6.2 mm)
Plug connector (manufacturer/type/protection degree)	Amphenol / H4 / IP68 or Multi Contact / MCA / IP67

The specifications in this datasheet are not guaranteed and are subject to change without prior notice.
 This datasheet complies with EN 50380:2003 requirements.

Yingli Green Energy Americas, Inc.

info@yingliamericas.com

Tel: +1 (888) 686-8820

YINGLISOLAR.COM/US | NYSE:YGE

© Yingli Green Energy Holding Co. Ltd. | YGE72CellSeries2012_EN_201206_V01


GENERAL CHARACTERISTICS

Dimensions (L/W/H)	77.56 in (1970 mm) / 38.98 in (990 mm) / 1.97 in (50 mm)
Weight	59.1 lbs (26.8 kg)

PACKAGING SPECIFICATIONS

Number of modules per pallet	21
Number of pallets per 50' container	28
Packaging box dimensions (L/W/H)	78 in (1990 mm) / 45 in (1130 mm) / 46 in (1170 mm)
Box weight	1351 lbs (613 kg)

Units: Inch (mm)



Warning: Read the Installation and User Manual in its entirety before handling, installing, and operating Yingli modules.

Our Partners



U.S. Soccer Powered by Yingli Solar

*Final equipment selections based on engineered analysis and market conditions. Greenskies reserves the right to use the equipment described here or an approved equal.



TECHNOLOGY

UTILITY-SCALE INVERTERS

SGI 225
SGI 250
SGI 266
SGI 300
SGI 500
SGI 500PE

FEATURES

- 97.5% CEC efficiency
- Highest CEC efficiency in the industry
- Built-in redundancy
- Fully-integrated design
- Customizable subcombiners
- 480 VAC or 600 VAC
- MODBUS communications
- User-interactive LCD

OPTIONS

- Uptime guarantee
- Stainless steel enclosure
- Web-based monitoring
- Built-in cellular connectivity

OPTIONS FOR UTILITIES

- Real power curtailment
- VAR support (Reactive power control)
- Voltage ride through
- Frequency ride through

 **SOLECTRIA**
RENEWABLES



UTILITY-SCALE INVERTERS

Solectria Renewables' SMARTGRID 225-500PE series of inverters boasts an industry leading 97.5% CEC weighted efficiency which translates into significantly greater energy production and cost savings over the lifetime of the system. The SGI line has been deployed in a large number of commercial and utility-scale PV systems across North America ranging from 200kW to multi-MW. Our customers find these inverters the most cost-effective, reliable and efficient in the market. The SGI product family offers options such as VAR support, voltage and frequency ride through, controlled ramp rates and real power curtailment. Such critical utility options, combined with unsurpassed efficiencies and the lowest nighttime tare loss in the industry, earmark the SGI Series as the premier inverter for next generation large commercial and utility-scale systems.



Built for the real world

*Final equipment selections based on engineered analysis and market conditions. Greenskies reserves the right to use the equipment described here or an approved equal.



SPECIFICATIONS	SGI 225	SGI 250	SGI 266	SGI 300	SGI 500	SGI 500PE
DC Input						
Absolute Maximum Input Voltage				625 VDC		
MPPT Input Voltage Range				300-500 VDC		
Maximum Operating Input Current	768 A	853 A	908 A	1026 A	1721 A	1712 A
AC Output						
Nominal Output Voltage			480 or 600 VAC, 3-Ph (3 wire standard, 4 wire optional)			
AC Voltage Range			-12%/+10%			
Continuous Output Power	225 kW	250 kW	266 kW	300 kW	500 kW	
Continuous Output Current	480 VAC 600 VAC	271 A 217 A	301 A 240 A	320 A 256 A	360 A 289 A	603 A 480 A
Maximum Backfeed Current				0 A		
Nominal Output Frequency				60 Hz		
Output Frequency Range				57-63 Hz		
Power Factor				Unity, >0.99		
Total Harmonic Distortion (THD)				≤3%		
Efficiency						
Peak Efficiency	98.0%	98.0%	98.0%	97.9%	97.9%	98.3%
CEC Efficiency	97.5%	97.5%	97.5%	97.5%	97.0%	97.5%
Tare Loss	28 W	28 W	28 W	28 W		32 W
Subcombines Options						
Fuses or breakers			6 positions, 225-400 A		8 positions, 225-400 A	
Fuses only			12 positions, 110-200 A		16 positions, 110-200 A	
			24 positions, 70-100 A		32 positions, 70-100 A	
Temperature						
Ambient Temperature Range (full power)			-40°F to +122°F (-40°C to +50°C)			
Storage Temperature Range			-40°F to +158°F (-40°C to +70°C)			
Relative Humidity (non-condensing)			5-95%			
Monitoring Options						
Web-based Monitoring (Inverter Direct)			SolrenView			
Revenue Grade Monitoring (Integrated)		400 A		800 A		
Sub-Array Monitoring (SolZone)		6 zones		8 zones		
Cellular Communication			SolrenView AIR			
Third Party Compatibility			Standard via MODBUS			
Testing & Certifications						
Safety Listings & Certifications			UL 1741/IEEE 1547, IEEE 1547.1, CSA C22.2#107.1, FCC part 15 B			
Maintenance outage power factor per IEEE 762-2006			0.1			
Testing Agency			ETL			
Warranty						
Standard			5 year			
Optional			10, 15, 20 year; extended service agreement; uptime guarantee			
Enclosure						
Transformer			Standard, fully-integrated (internal); External optional			
AC Breaker/DC Disconnect			Fully-integrated (internal)			
Dimensions (H x W x D)			79 in. x 109 in. x 41 in. (2007 mm x 2769 mm x 1041 mm)			
Shading Set Back			137* (3480 mm) at 30° solar elevation			
Weight	5170 lbs (2350 kg)	5650 lbs (2568 kg)	5650 lbs (2568 kg)	5650 lbs (2568 kg)	6980 lbs (3170 kg)	7107 lbs (3230 kg)
Enclosure Rating			NEMA 3R			
Enclosure Finish			Polyester powder coated steel; Optional stainless steel			

Copyright © Solectria Renewables, LLC. All information subject to change without notice. May 2013 V7



FS System

Features and Benefits

- ETL Listed
- High level of pre-assembled parts
- Proven extremely short installation time
- High quality and sustainable materials
- Easily accessible for ground and system maintenance
- Included certified engineering by professional engineer licensed in the location of the project
- Included soil tests and pull out tests on systems larger than 250 kW
- Options for in field adjustment, if needed

The Schletter FS Racking System has a proven worldwide product and installation history, with over 6 GW of ground mounted installations installed throughout the world with many FS installations ranking among the largest globally. Project specific system calculations and optimized material utilization address the ever increasing pressure to reduce costs in planning PV systems, taking into account balance of system (BoS). Complete structural calculations are provided for system design, while assuring compliance with current building codes and regulations.

With this established history and experience in ground mounted PV installations, the latest generation of the FS System offers a culmination of experience and the highest level of in-house pre-fabrication to date, while always maintaining the focus of making the overall cost of a PV system more competitive. **The result is an attractive system installed quickly, efficiently, and with the durability to last.**

Schletter stands behind the quality, durability, and functionality of its products and services its customers with professionalism. Because of our commitment to customer satisfaction, all Schletter systems have a voluntary 10-year warranty.

For more information, please visit www.schletter.us or call (520) 289-8700.



© Schletter Inc. • 3761 E Farnum Place • Tucson, Arizona 85706 • Tel: (520) 289-8700 • Fax: (520) 289-8696
E-mail: mail@schletter.us • www.schletter.us

1 / 4


*Final equipment selections based on engineered analysis and market conditions. Greenskies reserves the right to use the equipment described here or an approved equal.



Design Process

The first step in planning a ground mount system is thorough soil investigation and pull out tests of the pier driven posts at the project site. Such testing generally requires numerous soil samples and subsequent soil classifications, which are the basis for determining the quantitative bearing capacity. Testing includes:

- Vertical pull-out tests
- Lateral load tests
- Independent laboratory analysis of soil classification, corrosion potential, gradation and soil plasticity



Layout planning for the FS System can be accomplished using the Helios 3D™ layout software. Helios 3D features automatic, optimized drop shadow free placement of PV tables, making planning large systems virtually seamless. The program's sophisticated design tools and intuitive workflow allow users to complete days worth of project work in hours.

A two-part software system, Helios 3D consists of database management and an AutoCAD-based drafting interface. Helios 3D is a proven software system for utility scale solar planning in Europe and Schletter is the exclusive distributor of Helios 3D in North and South America.



Helios 3D Product Sheet

The FS foundation consists of hot-dip galvanized steel posts (also known as profiles) with a proprietary u-shaped design. The u-shape grants optimum anchorage in the soil while maximizing the post strength.



Insertion of the posts into the soil is performed quickly by means of a terrain versatile hydraulic ram (GAYK). This pile-driving technique is especially suitable for the installation of large power plants. The GAYK™ Ram features a track machine with center pounding for more efficient and accurate installations. Even difficult terrain conditions (gravel or stones) are possible; in case of bedrock, the GAYK can be equipped with a drilling unit. It is possible to ram posts on slopes up to 20 degrees.



GAYK Ram Product Sheet



Product Enhancements



Generation 6 is the result of experience gained through years of project planning and implementation with ground mount systems. The FS System Generation 6 is enhanced with new support designs that include a high level of pre-fabrication.

Four simple steps are done in the field:

- Drive the post into the ground
- Place the support on the post attachment head and bolt the lower strut
- Insert the locking plate at the attachment head
- Install the cross beams—that's it!

For any type of module, including the more fragile thin film modules, clamps are available. Schletter works with many module manufacturers to find the most appropriate clamping methods by performing structural FEM simulations with various modules and our clamping options.

The cross beams feature a profile geometry that is designed for optimal distribution of forces. Suitable bolt channels are integrated in all profiles for more efficient mounting. The cross beams are fixed to the support units by means of special mounting claws that are pre-assembled in the exact position required for the chosen module.



Time is Money

A reduction of BoS costs in the mechanical area is only possible by a minimization of the mounting time at the construction site. The materials of FS System Generation 6 are pre-assembled in the factory and are delivered to the construction site according to the customer's requested delivery schedule.





Technical Data

Material	<ul style="list-style-type: none"> Fastening elements, bolts: Stainless steel 304 and 316 Profiles (rails): Aluminum alloy 6105 T5 High life-expectancy, high residual value, no disposal costs Pile driven support posts: Steel, hot-dip galvanized with a G235 process <ul style="list-style-type: none"> - Easy plant re-powering due to modular design
Logistics	<ul style="list-style-type: none"> Quick and simple mounting Maximum level of prefabrication prior to shipment
Construction	<ul style="list-style-type: none"> Can be installed on uneven terrain Simple adjustment options Cost optimized configurations for framed and unframed modules
Accessories	<ul style="list-style-type: none"> Cable channels, cable ducts Components for potential equalization/grounding Clamps for every type of module Fastening systems for large laminate modules (OptiBond system)
Calculations	<ul style="list-style-type: none"> 100% code compliant designs for any locality Third-party structural PE, stamped drawings and calculations Individual system structural calculations based on geotechnical report Individual system design calculations based on regional load values Design loads according to IBC 2006 or 2009 Patented profile geometries with optimum material utilization Verification of all construction components based on FEM-calculation Earthquake simulation, optional
Available Third-Party Services	<ul style="list-style-type: none"> Geotechnical soil investigation and analysis Ramming of foundations Optional: rack mounting Optional: complete module mounting EPC services PPA formation
Terrain maintenance	<ul style="list-style-type: none"> Simple terrain maintenance due to single support <ul style="list-style-type: none"> - Specification of module height above ground possible
Grounding, Potential equalization	<ul style="list-style-type: none"> Grounding options available Components for the internal potential equalization
Warranty and Certifications	<ul style="list-style-type: none"> 10-year warranty, optional 20-years



Schletter Inc. D920114-10000000000000000000000000000000



TECHNOLOGY


Ecofoot²[®]

The Next Step.

Ecofoot²[®] is the first modular system that combines the benefits of polymer with integrated grounding and wire management. This pioneering combination maximizes installation efficiency while providing the most roof friendly design on the market.



Wire Management
Design accelerates the install process and reduces additional accessories on the roof.



Roof Friendly
Base contours and built-in gaskets provide a membrane friendly material and design. The drainage channels and weep holes encourage water flow.



Integrated Grounding
Eco Mid Clamp's attachment provides integrated grounding with the turn of a bolt.

340 W State St, Unit 22, Athens, OH 45701 740.249.1877 www.ecolibriumsolar.com



Ecolibrium Solar[®]

*Final equipment selections based on engineered analysis and market conditions. Greenskies reserves the right to use the equipment described here or an approved equal.



Ecofoot2® delivers the simplicity installers love, durability and roof friendly features site owner's demand, and cost savings that make projects possible. By combining the key components of the original Ecofoot®: speed, low part count, and cost effectiveness with the new features; integrated grounding, wire management, and increased weatherability. **Ecofoot2® is the next step in mounting systems.**

Additional Features

Advanced Material

Luran® ASA by Styron, a BASF company. The engineered resin has proven durability, ensuring Ecofoot® will withstand the toughest rooftop exposure for over 25 years.

Aerodynamic


Interior reflectors reduce the weight load placed on the roof structure while enhancing the wind load performance, permitting system installations on challenging roofs.

Adaptable

Modular system design promotes easy layout and accommodates uneven roof surfaces and drainage systems.

Flexible

Modules may be mounted in portrait or landscape.



Technical Specifications

System: Ballasted flat roof system with optional attachment method
Materials: Acrylonitrile styrene acrylate (ASA) Luran® by Styron
Dimensions: 26.5" L x 18.25" W x 6.5" H
Weight: 4 lbs
Module type: Framed PV module
Compatible modules: List of approved manufacturers: ecolibriumsolar.com
Module orientation: Landscape and portrait
Module tilt angle: 4°-12°
Module inter-row spacing: 10"
Roof pitch: 0°-5°
Ballast requirements: 4" x 5" x 16" roof paver
Installed weight: 3.5 psf
Building height: Meets ASCE 7-05 up to 60 feet, higher upon request
Exposure: Meets ASCE 7-05 category B, C, D
Wind load: Meets ASCE 7-05 up to 120 mph
Snow load: Meets ASCE 7-05 up to 70 psf
Seismic load: Meets ASCE 7-05 in all seismic zones
Warranty: 25 years



Ecolibrium Solar

*Final equipment selections based on engineered analysis and market conditions. Greenskies reserves the right to use the equipment described here or an approved equal.



CONCLUSION

We look forward to working with you.





10 Main Street, Suite E • Middletown, Connecticut 06457
tel: 860.398.5408 • email: info@greenskies.com • www.Greenskies.com



Greenskies Renewable Energy LLC
10 Main Street, Suite E
Middletown, CT 06457
www.greenskies.com

October 30, 2013

Letter of Intent Regarding PV Solar Installation

This Letter of Intent ("LOI") is entered into between Greenskies Renewable Energy LLC or one of its affiliated special purpose entities ("Greenskies") and the Theraplants LLC ("Theraplants"), as of the date written above ("Effective Date"). Greenskies and Theraplants are hereinafter collectively referred to as the "Parties" or individually as a "Party".

The purpose of this LOI is to describe the intent of the Parties to work in good faith to execute a Power Purchase Agreement ("PPA"). In the PPA, Greenskies shall engineer, procure, install and maintain a photovoltaic solar array ("System") on property owned by Theraplants ("Site"), as more fully described in Exhibit A, and Theraplants shall purchase from Greenskies one hundred percent (100%) of the electricity produced by the System. This LOI, in and of itself, does not create or constitute an enforceable agreement between the Parties. A formal PPA encompassing the terms and conditions specific to this project will subsequently be executed by both Parties.

In accordance with the terms and conditions of this LOI, the Parties agree as follows:

1. The Parties intend to execute a PPA for the installation of the System.
2. Such PPA and System installation shall be for the purpose of furthering Theraplants' formal response to the Request for Application provided and administered by the Connecticut Department of Consumer Protection ("DCP") pursuant to Chapter 420f of the Connecticut General Statutes, "*An Act Concerning The Palliative Use Of Marijuana*". Specifically, the System shall reduce the ecological footprint of Theraplants' production facility.
3. Upon the Effective Date of this LOI and for a period of one hundred and twenty (120) days thereafter ("Exclusivity Period") Theraplants shall not directly or indirectly solicit, participate in or initiate discussions or negotiations with (or provide any information to or engage in any transaction with) any person or entity other than Greenskies concerning the development of the System or the PPA.
4. The Parties will use best efforts to negotiate in good faith a PPA that will define the respective rights, obligations, interests and liabilities in connection with the installation of the System.

Miscellaneous.

- a. Costs and Expenses. Each Party shall bear its own costs and expenses in connection with this LOI, unless otherwise mutually agreed.
- b. Limitation of Liability. In no event shall either Party or any of their respective officers, directors, members, partners, shareholders, employees, agents or affiliates be liable for any special, indirect, non-compensatory, consequential, incidental, punitive or exemplary damages of any type, including lost profits, loss of business opportunity or business interruptions irrespective of whether such damages are reasonably foreseeable or whether such claims arise in contract, tort (including negligence, whether sole, joint, or concurrent or strict liability) or otherwise, arising out of this LOI.
- c. Termination. This LOI shall terminate on the first to occur of: (i) the expiration of the exclusivity period; or (ii) the execution of a PPA.
- d. Relationship. Neither Party can take any action to bind the other without the written consent of the other.
- e. Counterparts. This LOI may be executed in several counterparts (including by facsimile transmission or electronic transmission of a PDF file), each of which shall be deemed to be an original and all of which together shall constitute a single agreement.

AGREED AND ACCEPTED AS OF THE DATE FIRST WRITTEN ABOVE:

ACCEPTED:

ACCEPTED:

Signature

Greenskies Renewable Energy LLC
Name: Andrew Chester
Title: Manager
10 Main Street, Suite E
Middletown, CT 06457

Signature

Theraplants LLC
Name:
Title:

EXHIBIT A

Proposed Site

Site Address Theraplants LLC, 856 Echo Lake Road, Watertown, CT 06795

Type of Solar Array Ground-Mount, Roof-Mount

Approximate Area 155,000 ft²

System Size 700,000 kW

